[Antitumor effect of mIFN-λ3 in C57BL/6 mice model for papilloma tumors].
Although several years have passed since the determination of the human papilloma virus (HPV) as the causative agent for cervical cancer, a definitive treatment has not yet been found. Interferon-alpha (IFN-α) immunotherapy is one of the promising methods for tumor treatment, although numerous side effects were observed in clinical trials. Recently, a new type of interferon, lambda-interferon (IFN-λ), has been discovered with fewer side effects than IFN-α since its receptor repertoire is limited. IFN-λ has a series of activities including antiviral, anti-proliferative and anti-tumor actions. In the present study, the effects of IFN-α and IFN-λ on the TC1 papilloma tumor model in C57BL/6 mice were evaluated. TC1 cells were injected into the mice subcutaneously. Upon tumor formation, murine IFN, mIFN-α and mIFN-λ, expression plasmids were injected intratumorally in combination or alone. The survival time and tumor size as well as apoptosis in tumors and NK cytoxicity were measured after three injections. As compared with the control group, the remarkable results especially in the group which received mIFN-α and mIFN-λ together were obtained for all of the measured parameters. Although IFN-λ is a new member of the interferon family and its properties should be studied in detail, the data obtained suggests that the use of IFN-λ especially in combination with IFN-α could be considered as an effective strategy for papilloma cervical cancer immunotherapy.
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
H
H
Choobin
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.|Bamdad_T@modares.ac.ir.
T
T
Bamdad
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
H
H
Soleimanjahi
Department оf Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
H
H
Razavinikoo
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology*; D005260:Female; D015870:Gene Expression; D052162:Human papillomavirus 16 / Q000254:growth & development / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015552:Injections, Intralesional; D016898:Interferon-alpha / Q000096:biosynthesis / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D030361:Papillomavirus Infections / Q000276:immunology / Q000401:mortality / Q000628:therapy* / Q000821:virology; D010957:Plasmids / Q000008:administration & dosage* / Q000378:metabolism; D016019:Survival Analysis; D047368:Tumor Burden; D023041:Xenograft Model Antitumor Assays; D007378:Interleukins; D000095022:Interferon Lambda
D000970:Antineoplastic Agents; D016207:Cytokines; D016898:Interferon-alpha; C511668:interferon-lambda protein, mouse; D007378:Interleukins; D000095022:Interferon Lambda
immunotherapy; interferon-alpha; interferon-lambda; papilloma tumor